BioCentury
BioCentury
ARTICLE | Distillery Therapeutics

Chemically induced knockdown of SMARCA2/4 to treat AML

Inhua Muijrers-Chen
June 27, 2019 6:47 PM UTC

INDICATION: Acute myelogenous leukemia (AML)...

BCIQ Company Profiles

Boehringer Ingelheim GmbH

University of Dundee

BCIQ Target Profiles

SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 2 (SMARCA2) (BRM)

SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 4 (SMARCA4) (BRG1)

von Hippel-Lindau tumor suppressor (vHL)

BCIQ Company Profiles

Boehringer Ingelheim GmbH

University of Dundee

BCIQ Target Profiles

SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 2 (SMARCA2) (BRM)

SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 4 (SMARCA4) (BRG1)

von Hippel-Lindau tumor suppressor (vHL)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedInTwitterRSS
BioCentury
© 2023 BioCentury Inc. All Rights Reserved.
Copyright © 2023 BioCentury Inc. All Rights Reserved.
LinkedInTwitterRSS